FY2024 Earnings Forecast for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Analysts at HC Wainwright decreased their FY2024 earnings per share estimates for shares of PolyPid in a research report issued on Monday, December 16th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($4.83) for the year, down from their previous forecast of ($4.39). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($4.39) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2024 earnings at ($1.05) EPS, Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($2.41) EPS.

Separately, Craig Hallum began coverage on shares of PolyPid in a research report on Monday, November 4th. They issued a “buy” rating and a $10.00 target price for the company.

PolyPid Price Performance

Shares of PYPD opened at $3.50 on Thursday. PolyPid has a one year low of $2.37 and a one year high of $9.20. The stock’s fifty day moving average is $3.29 and its 200-day moving average is $3.57. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.00. The firm has a market capitalization of $16.79 million, a price-to-earnings ratio of -0.45 and a beta of 1.33.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC purchased a new stake in PolyPid Ltd. (NASDAQ:PYPD) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned approximately 2.89% of PolyPid as of its most recent filing with the Securities and Exchange Commission (SEC). 26.47% of the stock is owned by institutional investors and hedge funds.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.